Disease Research Treatment 
Drug Discovery World
SEPTEMBER 12, 2024
New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease. As expected, when the neurones were exposed to glutamate, they started to die.
Drug Discovery World
MARCH 24, 2023
Israeli researchers have developed a drug that is effective in treating a rare genetic muscle disease. The team demonstrated that the disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity. This is the first study to link muscle pain and weakness to statin use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 30, 2024
A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease. As we navigate the complex issue of chronic kidney disease, our commitment to patient-centred research remains unwavering.
Drug Discovery World
JUNE 26, 2024
Scientists at the University of Bristol have uncovered a new disease driving mechanism which they are aiming to target to help treat the development of atherosclerotic plaques. This unique award will allow us to develop a therapeutic to target this novel non-coding RNA, and validate its use in patients with heart disease.”
Drug Discovery World
APRIL 30, 2024
Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. Globally, there are more than 300 million people living with rare diseases. However, rare disease research can be fragmented. The £9.4 ($11.7)
Drug Discovery World
JUNE 11, 2024
Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs. About 5% of the world’s population are currently affected by an autoimmune disease, such as IBD, the umbrella term for Crohn’s disease and ulcerative colitis.
Drug Discovery World
APRIL 8, 2024
Scientists from Gwangju Institute of Science and Technology in Korea have discovered compound 11c, a potentially ground-breaking oral treatment for metabolic dysfunction-associated steatohepatitis. Their research signals a transformative leap in liver disease management, addressing both inflammation and fibrosis.
Expert insights. Personalized for you.
290 
Let's personalize your content